Vertex's painkiller was more effective than placebo at reducing the intensity of pain after 48 hours in two late-stage studies on more than 1,000 patients who had abdominoplasties, also known as ...

3 days ago · The U.S. Food and Drug Administration approved twice-daily JOURNAVX for the treatment of adults with moderate-to-severe acute pain. Vertex has established a wholesale acquisition cost for JOURNAVX in the United States of $15.50 per 50mg pill. Vertex is also evaluating suzetrigine in peripheral neuropathic pain (PNP).

2 days ago · Vertex’s drug works differently, blocking proteins that trigger pain signals that are later sent to the brain. “In trying to develop medicines that don’t have the addictive risks of opioid medicines, a key factor is working to block pain signaling before it gets to the brain,” Vertex’s Dr. David Altshuler, told The Associated Press last year.

2 days ago · The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals. The drug, Journavx, or suzetrigine, was approved to treat moderate to severe ...

2 days ago · The drug, called Journavx (suzetrigine) and manufactured by biotech company Vertex Pharmaceuticals, is a non-opioid painkiller, which doesn’t have addictive properties, unlike opioids often used ...

1 day ago · Vertex Pharmaceuticals has scored an FDA approval for Journavx (suzetrigine), a non-opioid pain reliever that could usher in a new era of nonaddictive therapy in the indication.. As an oral ...

2 days ago · To test the drug, Vertex, which is based in Boston, conducted two large clinical trials, each with approximately 1,000 patients who had pain from surgery. They were randomly assigned to get a ...